Arvind Remedies has established an Rs 250-crore manufacturing facility at Irungattukottai, near Chennai, in order to tap the US market. It has begun with testing and development of analgesic and cardiac generic drugs (tablets) at the plant, which will seek USFDA approval in next six months.
The company has also established a subsidiary in New Jersey to take care of its US strategy. It is likely to distribute its drugs in the US and also get into contract manufacturing for other American pharma companies.
